Information:

Error:

en ▾

Deutsch
English
Español
Italiano
Français
Português
Svenska
Nederlands

Login
Register
Search
ODM-XML file upload
Create data model
ODM-Edit tool
Metadata Registry
Help
About the MDM portal
Imprint

Login
Register

Actions ▾

ODM-XML file upload
Create data model
ODM-Edit tool
Metadata Registry
About the MDM portal

en ▾

Deutsch
English
Español
Italiano
Français
Português
Svenska
Nederlands

Search through specific fields of a model

The name of the data model contains study:: name:"study"
The description contains two terms:: description:"double blind"
The copyrightholder contains the term UKM:: copyrightholder:"UKM"
The uploader of the model is Martin Dugas:: uploader:"Martin Dugas"
The keywords contain cancer:: keyword:"cancer"

Refine the search with search operators

Search for groups of words with quotes:: "leukemia myeloid"
Use a wildcard to search for prefixes:: NCT*
With AND/OR/NOT find study without eye nor ear:: study AND NOT (eye OR ear)
Cancer must (+) occur, study not (-):: +cancer -study
You may connect the different search techniques:: name:"form*" AND routine

Info
Dialog
Download

Rating Ratings

Description:

RTOG-0525 TF: Treatment Summary Form NCT00304031 Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FE10D5B1-3CDE-10E3-E034-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FE10D5B1-3CDE-10E3-E034-0003BA3F9857

Keywords:

Brain Neoplasms

Central Nervous System Neoplasms

Versions (3) ▾

8/26/12
1/9/15
6/26/15

Uploaded on:

June 26, 2015

DOI:

No DOI assigned. To request one pleaselog in.

License:

Creative Commons BY-NC 3.0 Legacy

Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

RTOG-0525 TF: Treatment Summary Form NCT00304031

English

Details

Radiation Therapy Oncology Group Phase III Lung Pre-Op Chemotherapy vs. Pre-Op Concurrent Chemoradiation for NSCLC

StudyEvent: RTOG-0525 TF: Treatment Summary Form
1. Radiation Therapy Oncology Group Phase III Lung Pre-Op Chemotherapy vs. Pre-Op Concurrent Chemoradiation for NSCLC

RTOG clinical trial administrative data

Institution Name

Institution No.

Patient Initials

RTOG Patient ID

Yes

No

Assessment

Kg

cm

Karnofsky Performance Status

Dead (0)

Moribund, Fatal Processes Progressing Rapidly (10)

Normal, No Complaints, No Evidence Of Disease (100)

Very Sick, Hospitalization Indicated. Death Not Imminent (20)

Severely Disabled, Hospitalization Indicated. Death Not Imminent (30)

7 more items in the detailed view.

Neurological Function Status

Minor Neurologic Symptoms, Fully Active At Home/work Without Assistance (Minor neurologic symptoms, fully active at home/work without assistance)

Moderate Neurologic Symptoms, Fully Active At Home/work But Requires Assistance (Moderate neurologic symptoms, fully active at home/work but requires assistance)

Moderate Neurologic Symptoms, Less Than Fully Active At Home/work And Requires Assitance (Moderate neurologic symptoms, less than fully active at home/work and requires assistance)

No Neurologic Symptoms, Fully Active At Home/work Without Assistance (No neurologic symptoms, fully active at home/work without assistance)

Severe Neurologic Symptoms, Totally Inactive Requiring Complete Assistance At Home Or Institution, Unable To Work (Severe neurologic symptoms, totally inactive requiring complete assistance at home or institution, unable to work)

Disease Progression

Protocol Temozolomide Agent Administered Course Type

Concurrent Rt And Tmz (42 Days) (Concurrent RT and TMZ (42 days))

Tmz Days 1-21 Of 28 Day Cycle 12 Cycle Maximum (TMZ days 1-21 of 28 day cycle 12 cycle maximum)

Tmz Days 1-5 Of 28 Day Cycle 12 Cycle Maximum (TMZ days 1-5 of 28 day cycle 12 cycle maximum)

Is protocol chemotherapy continuing?

Yes

No

New or continuing adverse events

Yes

No

Assessment of Chemotherapy

Cycle Start Date

Treatment Course End Date

Total Dose of Agents/Drugs for this Cycle

Total No. of Doses

Reason for Treatment Modification

Adverse Event/side Effects/complications (Adverse event/side effects/complications)

Alternative Therapy (Alternative therapy)

Death On Study (Death on study)

Disease Progression, Relapse During Active Treatment (Disease progression, relapse during active treatment)

None (None)

6 more items in the detailed view.

Reason for Treatment Modification

Adverse Event/side Effects/complications (Adverse event/side effects/complications)

Alternative Therapy (Alternative therapy)

Death On Study (Death on study)

Disease Progression, Relapse During Active Treatment (Disease progression, relapse during active treatment)

None (None)

6 more items in the detailed view.

Alternative Therapy

Alternative Therapy

Reason Treatment Ended

Adverse Event/side Effects/complications (Adverse Event/Side Effects/Complications)

Alternative Therapy (Alternative therapy)

Death On Study (Death on study)

Disease Progression, Relapse During Active Treatment (Disease progression, relapse during active treatment)

Other (Other)

5 more items in the detailed view.

Footer

Signature of Person Completing This Form

Date Form Originally Completed

Back to the top of the page

Contact

Institute of Medical Informatics
Director: Prof. Dr. Martin Dugas
Albert-Schweitzer-Campus 1, A11
48149 Münster, Germany
Email : imi@uni-muenster.de

In collaboration with

Imprint
Disclaimer
Data Privacy

© 2020 University of Münster

Contact
Help
Cite

Contact

Please use this form for feedback, questions and suggestions for improvements.

Name*

Email*

Message*

Fields marked with * are required.

Login

Email:

Password:

Stay logged in

Forgot password?

Register